Tatva Chintan Pharma Chem Limited — Investor Meet, 04-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Tatva Chintan's financial results for the quarter and half-year showed Q2 FY26 operating revenue of INR123.5 Cr (+48% YoY) and EBITDA of INR22.2 Cr (+298% YoY). SDA surged to INR59.3 Cr (+119% YoY) from auto demand and Euro 7 norms. Management noted destocking is over, restocking beginning, confident in achieving 20-22% EBITDA margins as plant utilization improves. Electrolyte Salts target INR15 Cr revenue this year; hybrid battery commercialization by 2026. New agro/pharma products progress for Q3 FY26 onwards. Semiconductor chemicals moved to plant-scale trials in Q4 FY26, targeting full commercialization by 2028 with high margins. The new Jolva plant is operational January 2026.